Global /Taiwan /Healthcare /Biotechnology /6794

UnicoCell Biomed Co., Ltd.

6794

• TWSE: 6794 • Delayed

81.50TWD 0.3%

2.56 USD

As of 24 June 2026, UnicoCell Biomed Co., Ltd. has a market cap of $163.36M USD, ranking #22302 globally and #1075 in Taiwan. It ranks #2003 in the Healthcare sector, and #389 in the Biotechnology industry.

Global Rank

22302

Country Rank

1075

Sector Rank

2003

Industry Rank

389

Key Stats

Market Cap

$163.36MUSD

5.17B TWD

Enterprise Value

$141.28MUSD

4.49B TWD

Revenue (TTM)

$950.53KUSD

30.1M TWD

EBITDA (TTM)

-$3.67MUSD

-116.71M TWD

Net Income (TTM)

-$3.63MUSD

-114.84M TWD

PS Ratio

171.9

PB Ratio

6.0

Company Profile

Country (HQ)

Taiwan

Sector

Healthcare

Industry

Biotechnology

CEO

Yi-Pei Hung open_in_new

Founded

2011

Website

unicocell.com open_in_new

warningChart data may be delayed

1d	1w	1m	3m	6m	YTD	1y	3y	5y
0.3%	1%	2.7%	-8.8%	21%	-9.3%	24%	5.9%	114%

News

Markets

Exchange	Ticker	Price	Quotes
Taiwan Stock Exchange (TWSE) MIC: XTAI PRIMARY	6794 向榮生醫科技股份有限公司 Ordinary Shares ISIN: TW0006794001 Shares Out.: Shares Outstanding: 63.637M¹ Shares Float: 33.696M² TV: TradingView: TWSE: 6794 SA: Stock Analysis: TPE: 6794 YF: Yahoo Finance: 6794.TW GF: Google Finance: TPE: 6794 BA: Barron's: 6794 MS: Morningstar: XTAI: 6794	81.50 TWD	TV: TradingView: TWSE: 6794 SA: Stock Analysis: TPE: 6794 YF: Yahoo Finance: 6794.TW GF: Google Finance: TPE: 6794 BA: Barron's: 6794 MS: Morningstar: XTAI: 6794

¹Market cap is calculated using shares outstanding.

²Float shares are publicly tradable shares, excluding insider-held stock.

About UnicoCell Biomed Co., Ltd.

UnicoCell Biomed Co., Ltd. engages in the research and development of stem cell drugs in Taiwan and Japan. The company develops ELIXCYTE for the treatment of knee osteoarthritis and chronic kidney disease. It also operates an allogeneic adipose stem cell bank. In addition, the company offers autologous stem cell therapy; conditioned medium; UnicoVial, a cryogenic vial for the storage of cell products and biological samples under ultra-low temperature; and laboratory testing services, which include sterility, endotoxin, mycoplasma, and cell count and viability tests, as well as contract development and manufacturing organization (CDMO) services for cell-based products. UnicoCell Biomed Co., Ltd. was founded in 2011 and is based in Taipei, Taiwan.

Similar Companies

Industry: Biotechnology (Taiwan)

Name	Market Cap (USD) diff.	PE	Country
Caliway Biopharmaceuticals Co., Ltd. TWSE: 6919	$5.45B 172.76B TWD 3K%	-	Taiwan
Pell Bio-Med Technology Co., Ltd. TWSE: 6949	$1.61B 50.93B TWD 884%	-	Taiwan
Lin BioScience, Inc. TPEX: 6696	$1.07B 34.04B TWD 558%	-	Taiwan
HanchorBio Inc. TWSE: 7827	$709.71M 22.48B TWD 334%	-	Taiwan
HanchorBio Inc. TPEX: 7827	$599.34M 18.98B TWD 267%	-	Taiwan
Locus Cell Co., Ltd. TPEX: 06891	$570.39M 18.06B TWD 249%	-	Taiwan

Industry: Biotechnology (Global)

Name	Market Cap (USD) diff.	PE	Country
Amgen Inc. NASDAQ: AMGN	$182.42B 112K%	23.9	United States
Gilead Sciences, Inc. NASDAQ: GILD	$159.92B 98K%	19.0	United States
argenx SE EBR: ARGX	$47.1B 41.39B EUR 29K%	39.9	Netherlands
Samsung Biologics Co.,Ltd. KRX: 207940	$44.45B 68.19T KRW 27K%	35.5	South Korea
CSL Ltd. ASX: CSL	$41.65B 60.27B AUD 25K%	29.3	Australia
Lonza Group AG SIX: LONN	$41.62B 33.71B CHF 25K%	37.2	Switzerland

chevron_leftBack